Accessibility Menu
PureTech Health Plc logo

PureTech Health Plc(OTC) PTCHF

Market Cap$382.32MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-35%
5 Year-66%
1 Year-12%
1 Month-2%
$1.56
+0.00%
+0.00Today
PureTech Health Plc last closing stock price
MetricPriceDate
Last closeUSD 1.562026-08-06
PureTech Health Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.25%USD 1.532026-07-27
1 month-2.04%USD 1.602026-07-07
3 month-7.43%USD 1.692026-05-06
Year to date-8.24%USD 1.712025-12-29
1 year-11.61%USD 1.772025-07-24
3 year-40.06%USD 2.612023-08-07
5 year-65.88%USD 4.592021-08-06
Since inception-34.54%USD 2.392015-07-29

PureTech Health Plc Financials at a Glance

Market Cap

$382.32MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$8.99M

Net Income (TTM)

-$56.62M

EPS (TTM)

-$0.46

P/E Ratio

-3.43

Dividend

$0.00

Beta (Volatility)

0.33 (Low)

Price

$1.56

Volume

10,775

Open

$1.55

Previous Close

$1.56

Daily Range

$1.55 - $1.56

52-Week Range

$1.53 - $1.92

Estimated Earnings Date

Aug 27, 2026

PTCHF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About PureTech Health Plc

PureTech Health plc operates as a clinical-stage biopharmaceutical enterprise, focusing on the discovery and advancement of innovative therapeutic solutions. The company targets a diverse range of medical conditions, including inflammatory, fibrotic, and immunological disorders, as well as various cancers and neurological ailments.

Products and Services
  • KarXT, a treatment for schizophrenia and Alzheimer's-related psychosis
  • LYT-100, targeting lymphedema and lymphatic flow issues
  • Innovative platforms for oral delivery of biologics and vaccines
Growth Outlook
  • Strong pipeline with multiple candidates in clinical development
  • Recent collaborations with major pharmaceutical companies enhance market potential
  • Focus on addressing unmet medical needs in diverse therapeutic areas
Financial Highlights
  • Recent quarterly revenue of $2.82 million, showing growth potential
  • Cash and short-term investments totaling $279.34 million, providing financial stability
  • Current ratio of 6.59 indicates strong liquidity position
PureTech Health plc is positioned in the biotechnology sector, with a robust pipeline of innovative therapies aimed at addressing significant medical challenges. The company's strategic collaborations with leading pharmaceutical firms bolster its market presence and enhance its ability to bring novel treatments to market. Recent financial data reflects a solid liquidity position, which is crucial for supporting ongoing research and development efforts. The focus on unmet medical needs across various therapeutic areas positions PureTech Health as a compelling option for investors interested in the biotechnology landscape.
AI Generated • Jul 25, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Robert William Henry Lyne

Website

puretechhealth.com

Headquarters

Boston, MA 02210, US

PTCHF Financials

Key Financial Metrics (TTM)

Gross Margin

-468.52%

Operating Margin

-2113.80%

Net Income Margin

-2355.32%

Return on Equity

-31.98%

Return on Capital

-30.30%

Return on Assets

-20.57%

Earnings Yield

-29.15%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$382.32MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

244.38M

Volume

10.78K

Avg. Volume

2.35K

Financials (TTM)

Gross Profit

$5.66M

Operating Income

-$236.81M

EBITDA

-$59.91M

Operating Cash Flow

-$218.22M

Capital Expenditure

-$17.04K

Free Cash Flow

-$218.24M

Cash & ST Invst.

$279.34M

Total Debt

$19.79M

PureTech Health Plc Performance Analysis

PureTech Health Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 15,618,000-10.2%
20232023-12-31USD 3,330,000-78.7%
20242024-12-31USD 4,828,00045.0%
20252025-12-31USD 4,659,000-3.5%
PureTech Health Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3057.5%
Q42024-12-311298.3%
Q22025-06-30-54.0%
Q42025-12-3152.6%
PureTech Health Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.18-16.3%
20232023-12-31USD -0.2434.5%
20242024-12-31USD 0.21N/A
20252025-12-31USD -0.46N/A
PureTech Health Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30N/A
Q42024-12-31333.3%
Q22025-06-30-154.3%
Q42025-12-31-47.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$2.82M

+1444.8%

Gross Profit

$24.39M

+1518.8%

Gross Margin

8.63%

N/A

Market Cap

$382.32MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.78M

N/A

Employees

80

N/A

Net Income

-$65.53M

-58.5%

EBITDA

-$51.05M

-346.5%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$279.34M

-14.6%

Total Debt

$19.79M

-21.9%

Accounts Receivable

$8.14M

+242.7%

Inventory

$0.00

-100.0%

Long Term Debt

$11.10M

-39.2%

Short Term Debt

$8.50M

+19.8%

Return on Assets

-20.57%

N/A

Return on Invested Capital

-20.22%

N/A

Free Cash Flow

-$37.92M

+6.5%

Operating Cash Flow

-$37.91M

+6.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CLVLFClinuvel Pharmaceuticals Limited
$6.88+1.89%
NWBONorthwest Biotherapeutics, Inc.
$0.19+1.05%
BOVNFBioInvent International AB (publ)
$3.29+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About PTCHF

What is the current price of PureTech Health Plc?

PureTech Health Plc is trading at $1.56 per share.

What is the 52-week range for PureTech Health Plc?

Over the past 52 weeks, PureTech Health Plc has traded between $1.53 and $1.92.

How much debt does PureTech Health Plc have?

As of the most recent reporting period, PureTech Health Plc reported total debt of $19.76M.

How much cash does PureTech Health Plc have on hand?

PureTech Health Plc reported $254.07M in cash and cash equivalents in its most recent financial results.

What is PureTech Health Plc’s dividend yield?

PureTech Health Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services